Cargando…

A retrospective analysis of changes in lymphocyte levels in patients with multiple sclerosis during and after Tecfidera® treatment

BACKGROUND: There are currently no best practice recommendations for lymphocyte subset monitoring for patients with multiple sclerosis (pwMS) on disease-modifying therapies including Tecfidera® (dimethyl fumarate, DMF). However, there have been several cases of pwMS on DMF without severe lymphopenia...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baeva, Maria-Elizabeth, Baev, Philip Boris, Nelson, Jill, Kazimirchik, Anna, Vorobeychik, Galina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8283074/ https://www.ncbi.nlm.nih.gov/pubmed/34345437 http://dx.doi.org/10.1177/20552173211029674

Ejemplares similares

Repurposing Tecfidera for cancer
por: Booth, Laurence, et al.
Publicado: (2016)

Economic impact of new active substance status on EU payers’ budgets: example of dimethyl fumarate (Tecfidera(®)) for multiple sclerosis
por: Toumi, Mondher, et al.
Publicado: (2014)

Wdr1 and cofilin are necessary mediators of immune-cell-specific apoptosis triggered by Tecfidera
por: Poganik, Jesse R., et al.
Publicado: (2021)

Pharmacokinetics and Bioavailability of Monomethyl Fumarate Following a Single Oral Dose of Bafiertam™ (Monomethyl Fumarate) or Tecfidera(®) (Dimethyl Fumarate)
por: Lategan, Thomas W., et al.
Publicado: (2021)

Phase 2 randomized placebo controlled double blind study to assess the efficacy and safety of tecfidera in patients with amyotrophic lateral sclerosis (TEALS Study): Study protocol clinical trial (SPIRIT Compliant)
por: Vucic, Steve, et al.
Publicado: (2020)

Expression of the neuroprotective protein aryl hydrocarbon receptor nuclear translocator 2 correlates with neuronal stress and disability in models of multiple sclerosis
por: Rahim, Tissa, et al.
Publicado: (2018)

The neutrophil-to-lymphocyte ratio is associated with multiple sclerosis
por: Hasselbalch, IC, et al.
Publicado: (2018)

Multiple Sclerosis: Lipids, Lymphocytes, and Vitamin D
por: Hayes, Colleen E., et al.
Publicado: (2020)

MicroRNAs as T Lymphocyte Regulators in Multiple Sclerosis
por: Wang, Lin, et al.
Publicado: (2022)

Treatment effects of fingolimod in multiple sclerosis: Selective changes in peripheral blood lymphocyte subsets
por: Hjorth, Maria, et al.
Publicado: (2020)

The compartmentalized inflammatory response in the multiple sclerosis brain is composed of tissue-resident CD8+ T lymphocytes and B cells
por: Machado-Santos, Joana, et al.
Publicado: (2018)

Regulatory B and T lymphocytes in multiple sclerosis: friends or foes?
por: Vasileiadis, Georgios K., et al.
Publicado: (2018)

Autoreactive lymphocytes in multiple sclerosis: Pathogenesis and treatment target
por: Liu, Rongzeng, et al.
Publicado: (2022)

Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate
por: Spencer, Collin M., et al.
Publicado: (2015)

Impairment of Mitochondrial Redox Status in Peripheral Lymphocytes of Multiple Sclerosis Patients
por: Gonzalo, Hugo, et al.
Publicado: (2019)

The Role of Cytotoxic T-Lymphocyte Antigen 4 in the Pathogenesis of Multiple Sclerosis
por: Basile, Maria Sofia, et al.
Publicado: (2022)

A lipidomic approach to the study of human CD4(+) T lymphocytes in multiple sclerosis
por: Vergara, Daniele, et al.
Publicado: (2015)

Serum neurofilament light levels correlate with change of olfactory function in multiple sclerosis
por: Bsteh, Gabriel, et al.
Publicado: (2019)

Serum neurofilament levels reflect outer retinal layer changes in multiple sclerosis
por: Seitz, Caspar B., et al.
Publicado: (2021)

Effect of dimethyl fumarate on lymphocyte subsets in patients with relapsing multiple sclerosis
por: Buckle, Guy, et al.
Publicado: (2020)

Frequent somatic mosaicism in T lymphocyte subsets in individuals with and without multiple sclerosis
por: Van Horebeek, Lies, et al.
Publicado: (2022)

The neutrophil-to-lymphocyte and monocyte-to-lymphocyte ratios are independently associated with neurological disability and brain atrophy in multiple sclerosis
por: Hemond, Christopher C., et al.
Publicado: (2019)

Serum hepcidin levels in multiple sclerosis
por: Bsteh, Gabriel, et al.
Publicado: (2019)

Behavioral Changes in Patients with Multiple Sclerosis
por: Heldner, Mirjam R., et al.
Publicado: (2017)

Changes in peripheral T-lymphocyte subsets and serum cytokines in patients with systemic sclerosis
por: Guo, Rong-Hong, et al.
Publicado: (2022)

Loss of IL-10 secretion by regulatory B lymphocytes in multiple sclerosis patients
por: Michel, Laure, et al.
Publicado: (2011)

Expression of chemokine receptors on peripheral blood lymphocytes in multiple sclerosis and neuromyelitis optica
por: Uzawa, Akiyuki, et al.
Publicado: (2010)

Lymphocyte subtypes in relapsing–remitting multiple sclerosis patients treated with dimethyl fumarate
por: Chaves, C, et al.
Publicado: (2017)

The Neutrophil-to-Lymphocyte Ratio is Related to Disease Activity in Relapsing Remitting Multiple Sclerosis
por: D’Amico, Emanuele, et al.
Publicado: (2019)

The effects of dimethyl fumarate and fingolimod on T-cell lymphocyte proliferation in patients with multiple sclerosis
por: Reynolds, Audrey, et al.
Publicado: (2022)

miRTour: Plant miRNA and target prediction tool
por: Milev, Ivan, et al.
Publicado: (2011)

Search for Cellular Stress Biomarkers in Lymphocytes from Patients with Multiple Sclerosis: A Pilot Study
por: Grecchi, Sabrina, et al.
Publicado: (2012)

The Contribution of Gut Barrier Changes to Multiple Sclerosis Pathophysiology
por: Buscarinu, Maria Chiara, et al.
Publicado: (2019)

Superoxide Dismutase-1 Intracellular Content in T Lymphocytes Associates with Increased Regulatory T Cell Level in Multiple Sclerosis Subjects Undergoing Immune-Modulating Treatment
por: Rubino, Valentina, et al.
Publicado: (2021)

Affinity and catalytic heterogeneity of polyclonal myelin basic protein-hydrolyzing IgGs from sera of patients with multiple sclerosis
por: Legostaeva, Galina A, et al.
Publicado: (2010)

In Vivo Molecular Changes in the Retina of Patients With Multiple Sclerosis
por: Alba-Arbalat, Salut, et al.
Publicado: (2021)

Association between clinic-level quality of care and patient-level outcomes in multiple sclerosis
por: He, Anna H, et al.
Publicado: (2023)

High levels of alexithymia in patients with multiple sclerosis
por: Eboni, Audred Cristina Biondo, et al.
Publicado: (2018)

Corrigendum to Serum hepcidin levels in multiple sclerosis
Publicado: (2020)

B Lymphocytes in Multiple Sclerosis: Bregs and BTLA/CD272 Expressing-CD19+ Lymphocytes Modulate Disease Severity
por: Piancone, Federica, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_aiohvdoou8tfi1uhi62t3ak5lc